fenoterol vs fluticasone furoate/vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

fenoterol

Marketed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Partial signal

NCT02177370 · Phase 3 · terminated

This was a randomized, double-blind, active-controlled crossover study, but it enrolled only 19 participants and one of its two primary measures is a laboratory receptor-density biomarker rather than a direct asthma outcome, and no results have been posted.

No aligned efficacy figure on record for this race.

fluticasone furoate/vilanterol · Breo Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT01086384 · Phase 3 · completed

This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.

Reported efficacy

Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)

Result source: NCT01086384

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfenoterolfluticasone furoate/​vilanterol
Severe exacerbations, annualised rate—Not reported—Trial running · NCT05757102
Trough FEV1, change—Not reported0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
8 other results
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.3 vs 0.3 100/25 µg OD · wk 24 · n 397 · Phase 3 · secondary NCT01147848
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 wk 12 · n 417 · Phase 3 · secondary NCT03248128
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.3 vs 0.2 wk 12 · n 307 · Phase 3 · secondary NCT03248128
ACQ-5, change—Not reported-1.2 vs -1.1vs FFwk 24 · n 385NCT03248128
1 other result
  • -1.3 vs -1.1 wk 24 · n 291 · Phase 3 · secondary NCT03248128
OCS dose reduction—Not reported—Trial running · NCT05757102

Severe exacerbations, annualised rate

fenoterol
—Not reported
fluticasone furoate/​vilanterol
—Trial running · NCT05757102

Trough FEV1, change

fenoterol
—Not reported
fluticasone furoate/​vilanterol
0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
8 other results
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.3 vs 0.3 100/25 µg OD · wk 24 · n 397 · Phase 3 · secondary NCT01147848
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 wk 12 · n 417 · Phase 3 · secondary NCT03248128
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.3 vs 0.2 wk 12 · n 307 · Phase 3 · secondary NCT03248128

ACQ-5, change

fenoterol
—Not reported
fluticasone furoate/​vilanterol
-1.2 vs -1.1vs FFwk 24 · n 385NCT03248128
1 other result
  • -1.3 vs -1.1 wk 24 · n 291 · Phase 3 · secondary NCT03248128

OCS dose reduction

fenoterol
—Not reported
fluticasone furoate/​vilanterol
—Trial running · NCT05757102
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

fenoterol: no structured comparison results are available for Asthma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fenoterol: 0 of 4 rows · fluticasone furoate/vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​vilanterol
Dropout rate
—100/25 µga
NCT01086384 · Phase 3
show 16 more results
—200/25 µg OD
NCT01018186 · Phase 3
—100/25 µg OD
NCT01018186 · Phase 3
—
NCT03248128 · Phase 3 · Asthma · phase 3
10.9%100/25 µg OD
NCT01165138 · Phase 3
7.2%200/25 µg OD
NCT01686633 · Phase 3
9.2%100/25 µg OD
NCT01686633 · Phase 3
14.2%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
—100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
—100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
14.4%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
12.3%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—100/25 µga
NCT01086384 · Phase 3
show 16 more results
—200/25 µg OD
NCT01018186 · Phase 3
—100/25 µg OD
NCT01018186 · Phase 3
—
NCT03248128 · Phase 3 · Asthma · phase 3
1%100/25 µg OD
NCT01165138 · Phase 3
0.9%200/25 µg OD
NCT01686633 · Phase 3
0.9%100/25 µg OD
NCT01686633 · Phase 3
3.6%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
—100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
—100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
2.6%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
1.3%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
Serious AEs
4.1%100/25 µga
NCT01086384 · Phase 3
show 16 more results
0.5%200/25 µg OD
NCT01018186 · Phase 3
1.5%100/25 µg OD
NCT01018186 · Phase 3
1.1%
NCT03248128 · Phase 3 · Asthma · phase 3
0%100/25 µg OD
NCT01165138 · Phase 3
0.3%200/25 µg OD
NCT01686633 · Phase 3
1.2%100/25 µg OD
NCT01686633 · Phase 3
3%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
1%100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
1.4%100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
1.3%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
0.6%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0%100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100/25 µga
headache 18.6%
nasopharyngitis 15.4%
upper respiratory tract infection 7.2%
NCT01086384 · Phase 3
show 15 more results
200/25 µg OD
headache 17.3%
upper respiratory tract infection 14.9%
nasopharyngitis 9.4%
NCT01018186 · Phase 3
100/25 µg OD
headache 19.4%
upper respiratory tract infection 16.9%
nasopharyngitis 12.4%
NCT01018186 · Phase 3
nasopharyngitis 10.4%
upper respiratory tract infection 7%
rhinitis allergic 4.2%
NCT03248128 · Phase 3 · Asthma · phase 3
100/25 µg OD
nasopharyngitis 10% (placebo 7.4%)
headache 5% (placebo 3.9%)
NCT01165138 · Phase 3
200/25 µg OD
headache 8.4%
nasopharyngitis 7.2%
upper respiratory tract infection 2%
NCT01686633 · Phase 3
100/25 µg OD
headache 8.4%
nasopharyngitis 6.4%
upper respiratory tract infection 2.3%
NCT01686633 · Phase 3
200/25 µg OD
nasopharyngitis 12.7%
headache 5.6%
bronchitis 3.6%
NCT01134042 · Phase 3 · combination · Asthma · phase 3
100/25 µg OD
nasopharyngitis 11.4%
headache 8.4%
upper respiratory tract infection 6.2%
NCT01147848 · Phase 3 · Asthma · phase 3
100/25 µg QD
upper respiratory tract infection 6.8%
NCT02730351 · Phase 4 · registry result, not featured evidence
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
100/25 µg Once Daily
upper respiratory tract infection 7.2% (placebo 9.1%)
headache 4.6% (placebo 1.9%)
nasopharyngitis 4.6% (placebo 8.4%)
NCT01498679 · Phase 3 · registry result, not featured evidence
200/25 µg Once Daily
upper respiratory tract infection 8.4%
nasopharyngitis 3.9%
rhinitis allergic 3.2%
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100 µg/25 µg
bronchitis 4%
conjunctivitis 4%
headache 4%
NCT01453023 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/vilanterol

Severe Exacerbation Occurrence 15.3% (n=1009) vs 18.4% (n=1010) fluticasone furoate @ 76wk100/25 µg
event count · % of participants
NCT01086384 · Phase 3 · converted to % from 154 participants as posted
Severe Exacerbation Rate Annualized 200 vs 271 fluticasone furoate Severe asthma exacerbations @ 76wk100/25 µg
event rate · Severe asthma exacerbations
NCT01086384 · Phase 3
FEV1 Trough 0.457 vs 0.365 FF L @ 12wk200/25 µg OD
absolute change · L
NCT01686633 · Phase 3
show 8 more results
0.348 vs 0.265 fluticasone furoate L @ 36wk100/25 µg
NCT01086384 · Phase 3
0.368 vs 0.196 placebo L @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.441 vs 0.365 FF L @ 12wk100/25 µg OD
NCT01686633 · Phase 3
0.281 vs 0.3 Fluticasone Propionate/Salmeterol L @ 24wk100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
-0.129 vs -0.135 FP 100 mcg BD L @ 20wk100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.394 vs 0.201 FF L @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.312 vs 0.275 FF L @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
0.263 vs 0.245 FF L @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
FEV1 Weighted Mean 0-4h 2.082 vs 1.994 FF L @ 12wk
absolute value · L
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
1.762 vs 1.711 FF L @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Morning PEF 47.7 vs 19.1 FF L/min @ 12wk200/25 µg OD
absolute change · L/min
NCT01686633 · Phase 3
show 6 more results
46.2 vs 14 Fluticasone Propionate L/min200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
32.9 vs -0.4 placebo L/min @ 12wk100/25 µg OD
NCT01165138 · Phase 3
44.3 vs 19.1 FF L/min @ 12wk100/25 µg OD
NCT01686633 · Phase 3
43.6 vs -9.3 placebo L/min @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
11.9 vs 8.9 FF L/min @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
14.9 vs 9.3 FF L/min @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Rescue-free 24-h Period 25.9% (n=453) vs 25.8% (n=447) FF @ 12wk
absolute change · percentage points
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
27.3% (n=336) vs 25.6% (n=335) FF @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Symptom-free 24-h Period 25.7% (n=453) vs 24.6% (n=447) FF @ 12wk
absolute change · percentage points
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
27.2% (n=336) vs 25.8% (n=335) FF @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
ACQ-5 -1.21 vs -1.09 FF score @ 24wk
absolute change · score
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
-1.25 vs -1.13 FF score @ 24wk
NCT03248128 · Phase 3 · Asthma · phase 3
FEV1 Wm0 24 h 0.499 vs 0.366 FF L @ 12wk200/25 µg OD
absolute change · L
NCT01686633 · Phase 3
show 3 more results
0.513 vs 0.212 placebo L @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.474 vs 0.366 FF L @ 12wk100/25 µg OD
NCT01686633 · Phase 3
0.464 vs 0.328 FF L @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
Rescue-free 24-h Period 35.8% (n=346) vs 22.6% (n=346) FF @ 12wk200/25 µg OD
percent change · % of baseline
NCT01686633 · Phase 3
show 4 more results
37.1% (n=201) vs 17.8% (n=202) placebo @ 12wk100/25 µg OD
NCT01165138 · Phase 3
34.8% (n=345) vs 22.6% (n=346) FF @ 12wk100/25 µg OD
NCT01686633 · Phase 3
-3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
30.1% (n=153) vs 8.3% (n=154) placebo @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
Symptom-free 24-h Period 29% (n=346) vs 19.4% (n=346) FF @ 12wk200/25 µg OD
percent change · % of baseline
NCT01686633 · Phase 3
show 3 more results
32.5% (n=201) vs 14.6% (n=202) placebo @ 12wk100/25 µg OD
NCT01165138 · Phase 3
27.2% (n=345) vs 19.4% (n=346) FF @ 12wk100/25 µg OD
NCT01686633 · Phase 3
24.8% (n=153) vs 9% (n=154) placebo @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
AQLQ Total 0.8 vs 0.69 Fluticasone Propionate score @ 12wk200/25 µg Once Daily
absolute change · score
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
show 4 more results
0.91 vs 0.61 placebo score @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.84 vs 0.33 placebo score @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
0.74 vs 0.66 FF score @ 12wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.93 vs 0.88 FF score @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3

+ 19 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fenoterol's landscape · fluticasone furoate/vilanterol's landscape